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Introduction
Breast cancer is the second leading cause of mortality for 
women, and optimal strategies to detect early- stage can-
cer—without increasing the risk for overdiagnosis—con-
tinue to be investigated. National Cancer Institute 
Surveillance, Epidemiology and End Results Program 
(SEER) data document higher risks for late- stage cancer 
presentation and breast cancer mortality for women who 
are uninsured and who have Medicaid insurance, compared 
to commercially insured patients, underscoring the need 
to improve access to effective screening technologies in 
these vulnerable groups [1].
To this end, digital breast tomosynthesis (DBT) is poten-
tially an effective technology to aid the detection and 
diagnosis of breast cancer. The DBT technique reconstructs 
multiple- dimensional X- ray images of thin breast tissue 
planes, and is thought to improve breast cancer visualiza-
tion [2]. In practice, early observational data suggest a 
benefit to adding DBT to conventional two- dimensional 
digital mammography (DM), including improved cancer 
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Abstract
Digital breast tomosynthesis (DBT) has shown potential to improve breast cancer 
screening and diagnosis compared to digital mammography (DM). The FDA 
approved DBT use in conjunction with conventional DM in 2011, but coverage 
was approved by CMS recently in 2015. Given changes in coverage policies, it 
is important to monitor diffusion of DBT by insurance type. This study examined 
DBT trends and estimated associations with insurance type. From June 2011 
to September 2014, DBT use in 22 primary care centers in the Dartmouth 
- Brigham and Women’s Hospital Population- based Research Optimizing 
 Screening through Personalized Regimens research center (PROSPR) was 
examined among women aged 40–89. A longitudinal repeated measures analysis 
estimated the proportion of DBT performed for screening or diagnostic indications 
over time and by insurance type. During the study period, 93,182 mammograms 
were performed on 48,234 women. Of these exams, 16,506 DBT tests were 
performed for screening (18.1%) and 2537 were performed for diagnosis (15.7%). 
Between 2011 and 2014, DBT utilization increased in all insurance groups. 
However, by the latest observed period, screening DBT was used more frequently 
under private insurance (43.4%) than Medicaid (36.2%), Medicare (37.8%), 
other (38.6%), or no insurance (32.9%; P < 0.0001). No sustained differences 
in use of DBT for diagnostic testing were seen by insurance type. DBT is 
increasingly used for breast cancer screening and diagnosis. Use of screening 
DBT may be associated with insurance type. Surveillance is required to ensure 
that disparities in breast cancer screening are minimized as DBT becomes more 
widely available.
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detection and reduced call- back rates for false- positive 
results [3, 4, 5]. Breast cancer simulation models suggest 
adding DBT to DM may be cost- effective in a clinical 
population of women with dense breast [6]. Among women 
with heterogeneously and extremely dense breasts, the 
incremental cost of adding DBT imaging to screen for 
breast cancer has been estimated at $53,893 per quality- 
adjusted life year, and after 12 rounds of screening, an 
estimated 0.5 deaths and 405 false- positive findings per 
1000 women might be avoided [6]. The Food and Drug 
Administration (FDA) approved use of DBT in combina-
tion with DM for breast cancer screening for all women 
in 2011. However, at this writing, there are no clinical 
trial data to document the impact of DBT on mortality 
from breast cancer. The Centers for Medicare and Medicaid 
Services (CMS) recently approved reimbursement codes 
for DBT use, requiring no copayment for screening indi-
cations, although a copayment is required for diagnostic 
indications [7]. Currently, performing DBT in combination 
with DM is considered experimental by some commercial 
insurers, and is not uniformly covered.
Clinical uncertainty over appropriate uses of DBT, and 
variation in insurance coverage could contribute to access 
disparities. In particular, it is not known whether insur-
ance status contributes to early DBT utilization patterns, 
and whether disparities may exist for screening or diag-
nostic indications. Our current study uses data from 22 
primary care centers to (1) describe the uptake of DBT 
imaging since FDA approval in 2011, and (2) investigate 
the role of insurance type as a potential driver of patterns 
of DBT utilization in practices with access to DBT.
Methods
Study cohort and setting
The study cohort included women from 22 primary care 
centers undergoing breast imaging at one of the nine 
affiliated radiology facilities that offered DBT in addition 
to conventional DM for screening or diagnostic purposes 
between June 2011 and September 2014, the most recent 
year for which data were available. Each facility was affili-
ated with one of the 22 primary care centers that par-
ticipate in the Dartmouth (D) - Brigham and Women’s 
Hospital (BWH) Population- based Research Optimizing 
Screening through Personalized Regimens (PROSPR) breast 
cancer research center. We analyzed data on mammograms 
(DBT and DM) performed among women aged 40–89 years 
old. The D- BWH PROSPR research center studies primary 
care populations within the Dartmouth- Hitchcock (DH) 
Health system in New Hampshire and the Brigham and 
Women’s Hospital affiliated clinical network in 
Massachusetts.
Data sources and definitions
To obtain information regarding mammogram type (DBT 
vs. DM) and indication for exam (screening vs. diagnostic), 
multiple data abstraction procedures were used including 
manual and natural language processing strategies to 
abstract data from radiology information systems (RIS), 
billing claim codes, and from the electronic health record 
(EHR). Descriptions of these data collection procedures 
have been published previously, and demonstrate successful 
identification of indication data for DBT mammography 
[8, 9]. The insurance type (private/commercial insurance, 
Medicaid, Medicare, uninsured, or other payment) associ-
ated with each mammogram was obtained from the EHR.
We used EHR data and Census data to measure other 
covariates thought to influence DBT utilization: age at exam, 
breast density, race or ethnicity (non- Hispanic white, non- 
Hispanic black, non- Hispanic Asian/Pacific Islander, Hispanic, 
and other/unknown race and ethnicity), the region of care 
where mammograms were performed, and neighborhood 
zip code median household income. Breast density was 
assigned according to the American College of Radiology 
Breast Imaging Reporting and Data System (BI- RADS) criteria 
(almost entirely fatty, scattered fibroglandular density, het-
erogeneously dense, or extremely dense breasts) [10]. Among 
women with an unknown breast density on their index 
mammogram, we retrieved the breast density from a prior 
mammogram. For women without a prior mammogram 
(5119 or 5.5% of the cohort), the index study mammogram 
was retained and analyzed as an “unknown” breast density. 
Five- year estimates from the 2013 US Census American 
Community Survey [11] were used to classify neighborhood 
zip code median household income into quartiles based on 
the patient’s residential address. A region of care indicator 
was included to denote that mammography was performed 
at a BWH imaging facility in Massachusetts or at a southern 
DH imaging facility in New Hampshire. A northern DH 
radiology facility was removed from this analysis because 
DBT was initially implemented for research purposes.
Statistical analysis
In accordance with FDA- approved use of tomosynthesis, all 
DBT screening and diagnostic exams were conducted with 
an accompanying DM exam. We reported the total number 
of mammograms performed for screening and diagnostic 
purposes, and the proportion of these mammograms per-
formed as DBT during the study period, by patient char-
acteristics. To describe the longitudinal patterns of DBT 
uptake by insurance category, we conducted a repeated 
measures analysis using generalized estimating equations 
(GEE), with the outcome being an indicator of the mam-
mogram (conventional DM or DBT) being a DBT. This 
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analysis accounted for women having multiple exams during 
the study period. We described DBT utilization at 6- month 
intervals to examine diffusion of DBT use over time. We 
estimated associations between DBT use and insurance status 
within three periods of DBT uptake: early (June 2011 to 
June 2013), middle (July 2013 to June 2014), or late (July 
2014 to September 2014). A logit link and binomial variance 
were assumed under an exchangeable working covariance 
structure. Separate analyses were done for screening and 
diagnostic indications. The PROC GENMOD procedure was 
used in SAS 9.4 (SAS Institute Inc. 2015. SAS® 9.4, Cary, 
North Carolina, USA), with the LSMEANS option to produce 
predicted proportions of DBT exams by insurance and period.
Results
During the study period, 93,182 mammograms were per-
formed on 48,234 women (Appendix 1). Table 1 presents 
data on the proportion of DBT mammograms performed 
by study characteristics. The median age and interquartile 
range of the study cohort was 56 (49–65) years. Overall, 
16,506 (17.7%) of mammograms were performed as DBT. 
The proportion of screening DBT was 18.1% of all screening 
mammograms (N = 76,994), and the proportion of diagnostic 
mammograms was 15.7% of all diagnostic mammograms 
(N = 16,188). Across all the years of study, DBT was used 
to perform mammography more frequently for women with 
Table 1. Proportion of mammograms performed as DBT, by cohort characteristics and exam indication.
Proportion of mammograms performed as DBT1N (%)
Cohort characteristics
All mammograms  
N = 93,182
Screening mammograms  
N = 76,994
Diagnostic mammograms  
N = 16,188
All 16,506 (17.7) 13,969 (18.1) 2537 (15.7)
Age at Mammogram (years)
40–49 6044 (23.7) 5079 (24.8) 965 (19.3)
50–74 9936 (16.2) 8483 (16.5) 1453 (14.6)
75 + 526 (8.6) 407 (8.3) 119 (9.8)
Race/ethnicity2
NH white 12,667 (19.6) 11,039 (20.6) 1628 (14.7)
NH black 1153 (11.4) 867 (10.5) 286 (15.4)
NH Asian/Pacific Islander 614 (20.6) 531 (21.8) 83 (15.4)
Hispanic 1531 (12.7) 1081 (10.9) 450 (20.9)
Other/unknown 541 (15.5) 451 (15.5) 90 (15.7)
Insurance type3
Private 12,070 (19.5) 10,459 (20.4) 1611 (15.2)
Medicaid 790 (17.7) 550 (15.5) 240 (26.8)
Medicare 2549 (13.3) 2079 (13.2) 470 (13.9)
Other 792 (20.1) 619 (19.0) 173 (25.3)
Uninsured 288 (7.8) 247 (8.1) 41 (6.3)
Breast density
Fatty 619 (9.5) 504 (8.5) 115 (20.0)
Scattered fibroglandular 4520 (12.7) 3704 (12.4) 816 (14.2)
Heterogeneously dense 6906 (17.2) 5920 (18.5) 986 (12.3)
Extremely density 1122 (19.2) 939 (19.8) 183 (16.4)
Unknown 3339 (65.2) 2902 (65.6) 437 (62.8)
Neighborhood household income (zip code median)
<$61,060 4374 (19.1) 3580 (18.8) 794 (20.5)
$61,060–$78,814 3847 (16.2) 3200 (16.3) 647 (15.7)
$78,815–$100,429 4440 (19.9) 3892 (21.0) 548 (14.5)
>$100,429 3642 (16.0) 3120 (16.8) 522 (12.7)
Unknown 203 (13.9) 177 (15.1) 26 (9.2)
Region of care
BWH 8992 (11.0) 7016 (10.6) 1976 (13.1)
DH- South 7514 (64.3) 6953 (65.4) 561 (53.7)
DM, digital mammography (conventional); DBT, digital breast tomosynthesis; BWH, Brigham and women’s hospital; DH, Dartmouth- Hitchcock.
1Proportions are calculated as the number of DBT exams divided by the total number of mammograms performed (DBT/(DBT + DM)). All mammo-
grams (DBT and DM) for the cohort were performed where tomosynthesis capability was available during the study period between June 2011 and 
September 2014.
2The “Other” race category includes Native American and Alaskan Natives groups, which were of insufficient number to analyze separately.
3Of 93,182 mammograms, there were N = 29 mammograms with missing information for insurance status. “Other” insurance includes international 
payers, disability- related insurance, and occupational accident- related insurance and other payments.
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private insurance coverage (19.5%) than for those with 
Medicaid coverage (17.7%), Medicare coverage (13.3%), and 
uninsured women (7.8%; Table 1). Overall, DBT was used 
more frequently for women with extremely dense breasts 
(19.2%), and women of non- Hispanic Asian/Pacific Islander 
(20.6%) or non- Hispanic white (19.6%) race, while a non-
linear pattern was observed for median neighborhood income 
based on residential zip codes (Table 1).
Figure 1 shows the longitudinal trend in DBT utiliza-
tion for screening indication, by insurance type and adjusted 
for covariates. Across all insurance groups, use of screening 
DBT increased from 2.4% to 44.0% during the study 
period. The highest utilization increase was seen among 
exams covered by private insurance, from 2.5% in 2011 
to 46.0% in 2014. Use of DBT for diagnostic purposes 
increased from 2.4% to 36.9% across all insurance groups; 
no sustained differences in use of diagnostic DBT were 
observed by insurance type (figure not shown.)
Table 2 shows early, middle, and late phase estimates 
of DBT utilization associated with insurance status for 
screening and diagnostic use, respectively. During the early 
phase of DBT uptake, a higher proportion of screening 
mammograms were performed as DBT among Medicaid 
(5.4%) and Medicare beneficiaries (3.5%) compared to 
those privately insured (2.8%) or uninsured (1.0%; 
P < 0.0001). However, by the late phase of DBT uptake, 
screening DBT was used more frequently under private 
insurance (43.4%) than Medicaid (36.2%), Medicare 
(37.8%), or the uninsured (32.9%; P = 0.001). Other 
factors associated with increased use of screening DBT 
were younger age, higher income level, and dense breasts.
Figure 1. This figure shows time trends in utilization of screening DBT by insurance type. *Adjusted for age at mammogram, race, region of care 
(“BLINDED NAME”), breast density, and neighborhood household income. **Due to small cell sizes the first time interval is 1.75 years. ***P- values 
for chi- squared tests comparing insurance types at each time interval.
Table 2. Proportion of DBT (95% CI) for insurance type by exam indica-
tion for each time period1,2.
Screening indication
Diagnostic 
indication
Proportion  
DBT (95% CI)
Proportion DBT 
(95% CI)
Insurance type
Early phase: June 2011– 
June 2013
P < 0.0001 P < 0.0001
Private 2.8 (2.6–3.0) 3.9 (3.4–4.5)
Medicaid 5.4 (4.3–6.7) 5.0 (3.4–7.3)
Medicare 3.5 (2.9–4.2) 5.4 (4.2–6.9)
Other 3.9 (2.8–5.4) 7.0 (4.5–10.1)
Uninsured 1.0 (0.7–1.6) 1.5 (0.9–2.5)
Mid phase: July 2013– 
June 2014
P < 0.0001 P = 0.56
Private 16.8 (16.3–17.4) 21.9 (20.5–23.4)
Medicaid 14.1 (12.5–15.9) 25.2 (21.3–29.5)
Medicare 13.9 (12.9–14.9) 21.6 (19.1–24.4)
Other 15.7 (14.0–17.5) 23.3 (19.3–28.0)
Uninsured 12.5 (9.7–15.9) 25.7 (14.1–42.2)
Late phase: July 2014– 
Sep 2014
P = 0.001 P = 0.95
Private 43.4 (42.0–45.0) 36.0 (32.9–39.3)
Medicaid 36.2 (31.0–41.8) 35.9 (27.6–45.1)
Medicare 37.8 (35.0–40.6) 37.9 (32.5–43.6)
Other 38.6 (34.3–43.0) 36.0 (27.5–45.4)
Uninsured 32.9 (21.5–46.7) 29.9 (14.5–51.7)
DBT, Digital Breast Tomosynthesis.
1Models adjusted for age at mammogram, race, region of care (BWH, 
DH- South), breast density, and neighborhood household income.
2P- values for chi- squared tests comparing insurance types at each time 
interval.
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Similar insurance patterns of DBT uptake were found 
for diagnostic indication for the early phase. No insurance 
differences were found for diagnostic DBT in the middle 
(P = 0.56) and late phases (P = 0.99).
Discussion
We found a rapid increase in the use of DBT in 22 pri-
mary care practices in Massachusetts and New Hampshire 
from 2011 to 2014. By late 2014, screening DBT use varied 
by insurance status during all periods, and in the late 
period, ranged from 32.9% among the uninsured to 43.4% 
among privately insured women. No sustained differences 
in diagnostic DBT use were seen by insurance status.
There are few data on utilization of DBT across the 
US. Data from a 2012 survey of physician radiologist 
members of the Society of Breast Imaging (SBI) estimated 
30% of respondents used DBT for either screening or 
diagnostic purposes [12]. The SBI data report that DBT 
use in this early phase of uptake was highest in academic 
medical practices and in the northeast US. Our results 
may reflect higher utilization compared to other regions 
of the country. Our findings of increasing disparities 
between uninsured, publically insured, and privately 
insured women may reflect uncertainty about methods 
for billing for this technology. Of interest from the 2012 
survey, radiology respondents who used DBT reported 
that patients were required to sign a waiver accepting 
costs for DBT that were not covered by insurance, and 
that noncovered costs may have been charged to patients.
Our study has several limitations, including the geographic 
sampling frame, the inability to assess copayment charges, 
deductible levels for insurance plans, or other cost drivers 
of utilization that would give context to explain our results. 
Additionally, we note that the study period does not reflect 
the impact of newly assigned DBT billing codes from CMS, 
which may increase availability of DBT, and reduce uncov-
ered costs for publically insured women. In our assessment 
of breast density as a correlate of DBT use, we were able 
to obtain breast density information on the vast majority 
of mammograms. However, we note that 4.1% of mam-
mograms had breast density assigned based on a prior 
mammogram, which reflects a limitation of our data abstrac-
tion procedures. Breast density notification legislation is not 
likely to have played any role in the DBT utilization patterns 
we report since there was no legislation in effect within 
the study area throughout the study period, although MA 
enacted such a law that went into effect January 1, 2015.
Several strengths of our study include a longitudinal 
design, the ability to obtain direct measurement of mam-
mography utilization from EMR and claims data, and a 
large sample with detailed measures of covariates that may 
influence estimates of the association between insurance 
type and DBT use.
We conclude that DBT is increasingly used to perform 
mammography in the settings we studied, consistent with 
earlier survey data suggesting increasing popularity of the 
technology. Additional data are required to recommend 
DBT as an approach for screening to improve health 
outcomes. However, we find that use of DBT for screen-
ing in primary care sites may be patterned by insurance 
status. Surveillance is required to ensure that insurance 
status differences in access to DBT do not contribute to 
disparities in breast cancer screening as DBT technology 
becomes more widely available.
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Appendix 1 
Number of study participants (N = 48,234), and number of mammograms performed (N = 93,182), by women’s 
characteristics at the time the mammogram was performed.
Women’s characteristics
Total number of study participants 
N = 48,234 
N (%)
Total number of mammograms (DM 
or DBT) N = 93,182 
N (%)
Age at mammogram (years)
40–49 14,709 (30.5) 25,518 (27.4)
50–74 30,591 (63.4) 61,529 (66.0)
75+ 2934 (6.1) 6135 (6.6)
Race/ethnicity1
White, non- Hispanic 34,464 (71.5) 64,539 (69.3)
Black, non- Hispanic 4847 (10.0) 10,091 (10.8)
Asian/Pacific Islander, non- Hispanic 1601 (3.3) 2981 (3.2)
Hispanic 5622 (11.7) 12,084 (13.0)
Other/unknown 1700 (3.5) 3487 (3.7)
Insurance type2
Private 33,180 (68.8) 61,935 (66.5)
Medicaid 1894 (3.9) 4453 (4.8)
Medicare 8819 (18.3) 19,110 (20.5)
Other 1634 (3.4) 3944 (4.2)
Uninsured 2685 (5.6) 3711 (4.0)
Breast density
Fatty 2952 (6.1) 6499 (7.5)
Scattered fibroglandular 17,634 (36.5) 35,618 (40.8)
Heterogeneously dense 20,283 (42.1) 40,098 (45.0)
Extremely dense 2872 (6.0) 5848 (6.7)
Unknown 4493 (9.3) 5119 (5.5)
Neighborhood household income (zip code median)
<$61,060 12,289 (25.5) 18,678 (24.6)
$61,060–$78,814 11,973 (24.8) 24,219 (25.5)
$78,815–$100,429 12,188 (25.3) 23,205 (23.9)
>$100,429 11,035 (22.9) 25,624 (24.4)
Unknown 749 (1.6) 1456 (1.6)
Region of care
BWH 37,762 (78.3) 81,504 (87.5)
DH- South 10,472 (21.7) 11,678 (12.5)
DM, digital mammography; DBT, digital breast tomosynthesis; DX, diagnostic; NH, non- Hispanic; BWH, Brigham and women’s hospital; 
DH, Dartmouth- Hitchcock.
All mammograms (DBT and DM) for the cohort were performed where tomosynthesis capability was available during the study period between June 
2011 and September 2014.
1The “Other” race category includes Native American and Alaskan Natives groups, which were of insufficient number to analyze separately.
2Missing (N): Insurance type (26 women, 29 mammograms). “Other” insurance includes international payers, disability- related insurance, and 
occupational accident- related insurance and other payments.
